Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.
about
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyGetting TRAIL back on track for cancer therapySystemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.A framework for genomic biomarker actionability and its use in clinical decision makingEnhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicineAntitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma.TRAIL-coated leukocytes that kill cancer cells in the circulation.Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsLeukocytes as carriers for targeted cancer drug delivery.Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directionsProteomic tools for the characterization of cell death mechanisms in drug discovery.Targeting TRAIL in the treatment of cancer: new developments.Immune Therapy for Sarcomas.Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.Debunking the Delusion That Precision Oncology Is an Illusion.Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.Exceptional responders: in search of the science behind the miracle cancer cures.Challenging Standard-of-Care Paradigms in the Precision Oncology Era.Developing TRAIL/TRAIL death receptor-based cancer therapies.
P2860
Q27025344-A93A9C35-9D39-4205-91E9-CD1B0D162A38Q27027460-F38D3F43-E7EF-4666-832C-82B9DB9AFA4FQ33276109-F9A3C564-5C7A-474E-A8F3-3D77F3195D52Q34781122-2DD79B13-FD2D-4344-B36A-12B1497E76DAQ35590091-26A4D22F-F22A-4F98-A85F-D26332D5B80CQ36562114-DD54AE5D-86D7-4CE9-932D-72065F325ACFQ36665125-BC4DC077-315A-46FD-9EE4-05280FBFA49BQ37342909-B760B5F9-B770-4268-9D16-AFF2DA1650A8Q37492231-A5157E3D-6AE1-45DE-8EF6-477882DD4407Q37519654-6FF7C355-5016-42D0-A9B3-4762A5C7BC33Q37665702-DD0B7F51-9F4F-4E61-B595-24C2AA61AEDEQ38255704-D76C4653-B939-4C47-A3B8-B4884ED0BA83Q38340808-1FC0353B-C7C1-4A91-80F8-2213707C3BC7Q38364625-4E6F3EB7-D9C0-4101-AEA1-2BE091924747Q38500801-C3672F9F-9770-47C8-BBAF-813DC57F8743Q38742533-22FC9D18-22C4-402B-950B-92E39F6F65D9Q42037754-F27F9DC3-E422-4AD4-83E9-C73C2E5D2AB1Q44727423-80F51DF5-A055-49C9-B74D-0529C392DF0CQ45903630-E6DDFB00-D5EB-49D4-A688-459910CA3ED5Q46539715-4DB8F2F0-73AD-483F-AC71-6D333F619E7DQ47707153-6CDC1464-9B47-4E86-8D6C-472378DDF74DQ47712951-E9FD64D5-1981-4B2E-AFEC-223EF111678DQ48639229-EF02FF61-CB92-49E6-A63F-4BCB95CBDED9Q49835188-3FCDC6EA-C71C-474E-851F-E7488F89BB6FQ53701901-40EA225D-C899-4C59-B37A-2BAD174AA305
P2860
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting the apoptotic pathwa ...... ic receptor (DR4/DR5) agonist.
@ast
Targeting the apoptotic pathwa ...... ic receptor (DR4/DR5) agonist.
@en
type
label
Targeting the apoptotic pathwa ...... ic receptor (DR4/DR5) agonist.
@ast
Targeting the apoptotic pathwa ...... ic receptor (DR4/DR5) agonist.
@en
prefLabel
Targeting the apoptotic pathwa ...... ic receptor (DR4/DR5) agonist.
@ast
Targeting the apoptotic pathwa ...... ic receptor (DR4/DR5) agonist.
@en
P2093
P2860
P1476
Targeting the apoptotic pathwa ...... ic receptor (DR4/DR5) agonist.
@en
P2093
Avi Ashkenazi
Jamie Buryanek
Jonathan Trent
Robert E Brown
Vivek Subbiah
P2860
P304
P356
10.1158/1535-7163.MCT-12-0358
P577
2012-08-20T00:00:00Z